1. Home
  2. GNPX vs SINT Comparison

GNPX vs SINT Comparison

Compare GNPX & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • SINT
  • Stock Information
  • Founded
  • GNPX 2009
  • SINT 1996
  • Country
  • GNPX United States
  • SINT United States
  • Employees
  • GNPX N/A
  • SINT N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • SINT Medical/Dental Instruments
  • Sector
  • GNPX Health Care
  • SINT Health Care
  • Exchange
  • GNPX Nasdaq
  • SINT Nasdaq
  • Market Cap
  • GNPX 6.6M
  • SINT 7.9M
  • IPO Year
  • GNPX 2018
  • SINT 2014
  • Fundamental
  • Price
  • GNPX $0.23
  • SINT $3.20
  • Analyst Decision
  • GNPX
  • SINT Strong Buy
  • Analyst Count
  • GNPX 0
  • SINT 1
  • Target Price
  • GNPX N/A
  • SINT $28.00
  • AVG Volume (30 Days)
  • GNPX 3.6M
  • SINT 55.8K
  • Earning Date
  • GNPX 08-08-2025
  • SINT 08-12-2025
  • Dividend Yield
  • GNPX N/A
  • SINT N/A
  • EPS Growth
  • GNPX N/A
  • SINT N/A
  • EPS
  • GNPX N/A
  • SINT N/A
  • Revenue
  • GNPX N/A
  • SINT $2,569,000.00
  • Revenue This Year
  • GNPX N/A
  • SINT $3.26
  • Revenue Next Year
  • GNPX N/A
  • SINT $21.87
  • P/E Ratio
  • GNPX N/A
  • SINT N/A
  • Revenue Growth
  • GNPX N/A
  • SINT N/A
  • 52 Week Low
  • GNPX $0.20
  • SINT $1.71
  • 52 Week High
  • GNPX $3.97
  • SINT $8.60
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 40.22
  • SINT 54.73
  • Support Level
  • GNPX $0.22
  • SINT $3.05
  • Resistance Level
  • GNPX $0.32
  • SINT $3.38
  • Average True Range (ATR)
  • GNPX 0.03
  • SINT 0.23
  • MACD
  • GNPX -0.01
  • SINT -0.00
  • Stochastic Oscillator
  • GNPX 22.07
  • SINT 45.12

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.

Share on Social Networks: